Showing 1 - 10 results of 10 for search 'J. Diels', query time: 7.32s
Refine Results
-
1
-
2
-
3
Options for calibrating CERES-maize genotype specific parameters under data-scarce environments. by A A Adnan, J Diels, J M Jibrin, A Y Kamara, P Craufurd, A S Shaibu, I B Mohammed, Z E H Tonnang
Published 2019-01-01
Article -
4
P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE by M-C Vekemans, M Delforge, S Anguille, J Depaus, N Meuleman, A Van de Velde, I Vande Broek, D Strens, S Van Hoorenbeeck, EJ Moorkens, J Diels, F Ghilotti, S Dalhuisen, S Vandervennet
Published 2022-04-01
Article -
5
Impact of agricultural management on soil aggregates and associated organic carbon fractions: analysis of long-term experiments in Europe by I. S. Panagea, A. Apostolakis, A. Berti, J. Bussell, P. Čermak, J. Diels, A. Elsen, H. Kusá, I. Piccoli, J. Poesen, J. Poesen, C. Stoate, M. Tits, Z. Toth, G. Wyseure
Published 2022-10-01
Article -
6
P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE L... by H. Einsele, P. Moreau, M. Delforge, N. W. van de Donk, F. Ghilotti, J. Diels, A. Elsada, V. Strulev, L. Pei, R. Kobos, J. Smit, M. Slavcev, K. Weisel, M.-V. Mateos
Published 2022-06-01
Article -
7
P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 A... by O. Decaux, C. Hulin, A. Perrot, M. Macro, L. Frenzel, J. Diels, N. J. Perualila, F. Ghilotti, B. Haefliger, E. Goldsztajn, S. Vernet, J. Thevenon, M. Willaime, N. Texier, J. M. Schecter, D. Madduri, C. Jackson, S. Valluri, P. Moreau
Published 2022-06-01
Article -
8
P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPO... by K. Weisel, M.-V. Mateos, L. Vincent, T. Martin, J. G. Berdeja, A. Jakubowiak, S. Jagannath, Y. Lin, P. Thilakarathne, F. Ghilotti, J. Diels, B. Haefliger, C. Hague, A. Gonzalez, J. M. Schecter, K. S. Gries, V. Strulev, T. Nesheiwat, L. Pacaud, H. Einsele, P. Moreau
Published 2022-06-01
Article -
9
P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP... by M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan
Published 2022-06-01
Article -
10
PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON by L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau
Published 2022-06-01
Article